ipratropium bromide

CLINICAL USE

Anticholinergic bronchodilator:Reversible airways obstruction, particularly in COPD

DOSE IN NORMAL RENAL FUNCTION

Nebuliser solution: 250–500 micrograms 3– 4 times dailyInhaler: 20–80 micrograms 3–4 times daily

PHARMACOKINETICS

Molecular weight :430.4

%Protein binding :<20

%Excreted unchanged in urine : <1

Volume of distribution (L/kg) :4.6

half-life – normal/ESRD (hrs) :1.6/–

DOSE IN RENAL IMPAIRMENT

GFR (mL/MIN)

20 to 50 : Dose as in normal renal function

10 to 20 : Dose as in normal renal function

<10 : Dose as in normal renal function

DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES

CAPD :Not dialysed. Dose as in normal renal function

HD :Not dialysed. Dose as in normal renal function

HDF/high flux :Not dialysed. Dose as in normal renal function

CAV/VVHD :Not dialysed. Dose as normal renal function

IMPORTANT DRUG INTERACTIONS

Potentially hazardous interactions with other drugs

None known

ADMINISTRATION

Reconstition

–

Route

Inhaled

Rate of Administration

Nebuliser: according to nebuliser

Comments

The dose of nebuliser solution may need to be diluted in order to obtain a final volume suitable for the nebuliserSterile sodium chloride 0.9% should be used if dilution is required

OTHER INFORMATION

Following inhalation, only a small amount of ipratropium reaches the systemic circulation. Any swallowed drug is poorly absorbed from the GI tract

Tags: post-by-auto-php